Necitumumab plus Gemcitabine and Cisplatin as First-Line Therapy in Patients with Stage IV EGFR- Expressing Squamous Non-Small-Cell Lung Cancer: German Subgroup Data from an Open-Label, Randomized Controlled Phase 3 Study (SQUIRE)

Martin Reck; Michael Thomas; Cornelia Kropf-Sanchen; Jörg Mezger; Mark A. Socinski; Henrik Depenbrock; Victoria Soldatenkova; Jacqueline Brown; Thomas Krause; Nick Thatcher

doi:10.1159/000448085

Necitumumab plus Gemcitabine and Cisplatin as First-Line Therapy in Patients with Stage IV EGFR- Expressing Squamous Non-Small-Cell Lung Cancer: German Subgroup Data from an Open-Label, Randomized Controlled Phase 3 Study (SQUIRE)

Oncology Research and Treatment ◽

10.1159/000448085 ◽

2016 ◽

Vol 39 (9) ◽

pp. 539-547 ◽

Cited By ~ 7

Author(s):

Martin Reck ◽

Michael Thomas ◽

Cornelia Kropf-Sanchen ◽

Jörg Mezger ◽

Mark A. Socinski ◽

...

Keyword(s):

Stage Iv ◽

Small Cell ◽

Small Cell Lung ◽

First Line ◽

Open Label ◽

Phase 3 ◽

Randomized Controlled ◽

First Line Therapy ◽

Line Therapy ◽

Gemcitabine And Cisplatin

Download Full-text

Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): an open-label, randomised, controlled phase 3 trial

The Lancet Oncology ◽

10.1016/s1470-2045(15)00021-2 ◽

2015 ◽

Vol 16 (7) ◽

pp. 763-774 ◽

Cited By ~ 252

Author(s):

Nick Thatcher ◽

Fred R Hirsch ◽

Alexander V Luft ◽

Aleksandra Szczesna ◽

Tudor E Ciuleanu ◽

...

Keyword(s):

Stage Iv ◽

Small Cell ◽

Small Cell Lung ◽

First Line ◽

Open Label ◽

Phase 3 ◽

First Line Therapy ◽

Line Therapy ◽

Randomised Controlled ◽

Gemcitabine And Cisplatin

Download Full-text

Necitumumab plus pemetrexed and cisplatin as first-line therapy in patients with stage IV non-squamous non-small-cell lung cancer (INSPIRE): an open-label, randomised, controlled phase 3 study

The Lancet Oncology ◽

10.1016/s1470-2045(15)70046-x ◽

2015 ◽

Vol 16 (3) ◽

pp. 328-337 ◽

Cited By ~ 75

Author(s):

Luis Paz-Ares ◽

Jörg Mezger ◽

Tudor E Ciuleanu ◽

Jürgen R Fischer ◽

Joachim von Pawel ◽

...

Keyword(s):

Lung Cancer ◽

Stage Iv ◽

Small Cell ◽

Small Cell Lung ◽

First Line ◽

Open Label ◽

Phase 3 ◽

First Line Therapy ◽

Line Therapy ◽

Randomised Controlled

Download Full-text

A phase III, randomized, open-label trial of nivolumab (anti-PD-1; BMS-936558, ONO-4538) versus investigator's choice chemotherapy (ICC) as first-line therapy for stage IV or recurrent PD-L1+ non-small cell lung cancer (NSCLC).

Journal of Clinical Oncology ◽

10.1200/jco.2014.32.15_suppl.tps8128 ◽

2014 ◽

Vol 32 (15_suppl) ◽

pp. TPS8128-TPS8128 ◽

Cited By ~ 4

Author(s):

David Paul Carbone ◽

Mark A. Socinski ◽

Allen C. Chen ◽

Prabhu Bhagavatheeswaran ◽

Martin Reck ◽

...

Keyword(s):

Lung Cancer ◽

Stage Iv ◽

Small Cell ◽

Phase Iii ◽

Small Cell Lung ◽

First Line ◽

Open Label ◽

First Line Therapy ◽

Line Therapy ◽

Open Label Trial

Download Full-text

Efficacy and Safety of First-Line Necitumumab Plus Gemcitabine and Cisplatin Versus Gemcitabine and Cisplatin in East Asian Patients with Stage IV Squamous Non-small Cell Lung Cancer: A Subgroup Analysis of the Phase 3, Open-Label, Randomized SQUIRE Study

Cancer Research and Treatment ◽

10.4143/crt.2016.423 ◽

2017 ◽

Vol 49 (4) ◽

pp. 937-946 ◽

Cited By ~ 5

Author(s):

Keunchil Park ◽

Eun Kyung Cho ◽

Maximino Bello ◽

Myung-Ju Ahn ◽

Sumitra Thongprasert ◽

...

Keyword(s):

Stage Iv ◽

Small Cell ◽

Efficacy And Safety ◽

Small Cell Lung ◽

First Line ◽

Open Label ◽

Phase 3 ◽

Asian Patients ◽

East Asian Patients ◽

Gemcitabine And Cisplatin

Download Full-text

195TiP A phase 3, randomized, double-blind study of epacadostat plus pembrolizumab vs pembrolizumab as first-line therapy for metastatic non-small cell lung cancer (mNSCLC) expressing high PD-L1 levels (ECHO-305/KEYNOTE-654)

Journal of Thoracic Oncology ◽

10.1016/s1556-0864(18)30468-4 ◽

2018 ◽

Vol 13 (4) ◽

pp. S116-S117

Author(s):

L. Paz-Ares ◽

S. Rubin ◽

Y. Zhao ◽

L. Xu ◽

A. Samkari ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Small Cell ◽

Double Blind Study ◽

Small Cell Lung ◽

First Line ◽

Phase 3 ◽

Double Blind ◽

First Line Therapy ◽

Line Therapy

Download Full-text

Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study

The Lancet Oncology ◽

10.1016/s1470-2045(14)70381-x ◽

2014 ◽

Vol 15 (11) ◽

pp. 1236-1244 ◽

Cited By ~ 383

Author(s):

Takashi Seto ◽

Terufumi Kato ◽

Makoto Nishio ◽

Koichi Goto ◽

Shinji Atagi ◽

...

Keyword(s):

Small Cell ◽

Egfr Mutations ◽

Phase 2 ◽

Small Cell Lung ◽

First Line ◽

Open Label ◽

Multicentre Phase ◽

First Line Therapy ◽

Line Therapy ◽

Phase 2 Study

Download Full-text

Randomized controlled trial of lobaplatin plus etoposide vs. cisplatin plus etoposide as first‑line therapy in patients with extensive‑stage small cell lung cancer

Oncology Letters ◽

10.3892/ol.2019.10125 ◽

2019 ◽

Cited By ~ 1

Author(s):

Ying Cheng ◽

Yun Fan ◽

Xiaoqing Liu ◽

Yunpeng Liu ◽

Jiwei Liu ◽

...

Keyword(s):

Lung Cancer ◽

Randomized Controlled Trial ◽

Controlled Trial ◽

Small Cell ◽

Small Cell Lung ◽

First Line ◽

Randomized Controlled ◽

First Line Therapy ◽

Line Therapy ◽

Extensive Stage

Download Full-text

P3-135: Results of an open-label, Phase II trial of nanoparticle albumin bound paclitaxel (nab-paclitaxel), carboplatin, and bevacizumab as first-line therapy in patients with advanced non-squamous non-small cell lung cancer (NSCLC)

Journal of Thoracic Oncology ◽

10.1097/01.jto.0000284110.26459.89 ◽

2007 ◽

Vol 2 (8) ◽

pp. S736-S737

Author(s):

Craig Reynolds ◽

David Barrera ◽

Duy Quoc Vu ◽

Robert Jotte ◽

Alexander I. Spira ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Phase Ii Trial ◽

Small Cell ◽

Small Cell Lung ◽

First Line ◽

Open Label ◽

First Line Therapy ◽

Line Therapy ◽

Open Label Phase

Download Full-text

Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line treatment for stage IV squamous non-small cell lung cancer: A phase 1b and randomized, open-label, multicenter, phase 2 trial in Japan

Lung Cancer ◽

10.1016/j.lungcan.2019.01.005 ◽

2019 ◽

Vol 129 ◽

pp. 55-62 ◽

Cited By ~ 6

Author(s):

Satoshi Watanabe ◽

Hiroshige Yoshioka ◽

Hiroshi Sakai ◽

Katsuyuki Hotta ◽

Mitsuhiro Takenoyama ◽

...

Keyword(s):

Stage Iv ◽

Small Cell ◽

Phase 2 ◽

Small Cell Lung ◽

First Line ◽

Open Label ◽

Phase 2 Trial ◽

Multicenter Phase ◽

Phase 1B ◽

Gemcitabine And Cisplatin

Download Full-text

A phase III, randomized, open-label, multicenter study of SHR-1210 (anti-PD-1 antibody) in combination with pemetrexed and carboplatin as first line therapy in subjects with advanced/metastatic non-squamous non-small cell lung cancer

Annals of Oncology ◽

10.1093/annonc/mdy292.126 ◽

2018 ◽

Vol 29 ◽

pp. viii545 ◽

Cited By ~ 1

Author(s):

F. Wu ◽

G. Gao ◽

C. Zhou ◽

X. Kang ◽

Y. Zhou

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Multicenter Study ◽

Small Cell ◽

Phase Iii ◽

Small Cell Lung ◽

First Line ◽

Open Label ◽

First Line Therapy ◽

Line Therapy

Download Full-text